Paper Details

  1. Home
  2. Paper Details

Participant experiences and facilitators and barriers to pill use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco.

Author: AmicoK Rivet, BuchbinderSusan, GilmoreHailey J, GoicocheaPedro, GrantRobert, KoesterKimberly Ann, LiuAlbert, LubenskyDavid, McMahanVanessa, VargasLorena

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

High adherence to daily PrEP (emtricitabine/tenofovir disoproxil fumarate) for HIV prevention was linked to established routines, client-centered counseling, and positive relationships with healthcare providers. Future interventions should focus on these aspects to improve adherence.
Paper Details　
Original Abstract of the Article :
In 2010, the iPrEx study demonstrated efficacy of daily emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) pre-exposure prophylaxis (PrEP) in reducing HIV acquisition among men who have sex with men. Adherence to study product was critical for PrEP efficacy, and varied considerably, with FTC/TDF ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3791030/

データ提供：米国国立医学図書館（NLM）

PrEP Adherence: Understanding the Experiences of Men Who Have Sex with Men

The iPrEx study, like a groundbreaking expedition into the desert of HIV prevention, demonstrated the efficacy of pre-exposure prophylaxis (PrEP) in reducing HIV acquisition among men who have sex with men. This study, like a seasoned traveler investigating the nuances of a new territory, delves into the experiences of iPrEx participants in San Francisco, exploring the factors that influence adherence to daily PrEP medication.

PrEP Adherence: A Journey of Routine and Support

The study reveals that PrEP adherence, like a well-established caravan route, is facilitated by establishing and maintaining a consistent routine. Participants valued the healthcare provided by the study and the supportive relationships they developed with staff, creating an environment conducive to adherence. It's like a bustling desert oasis, where travelers feel welcomed and supported.

Barriers to Adherence: Navigating the Challenges

The study also identifies barriers to PrEP adherence, such as changes in routine, side effects, and stress. These obstacles, like unexpected sandstorms, can disrupt the flow of a journey. Understanding these barriers is crucial for developing strategies to enhance adherence and ensure the effectiveness of PrEP.

Dr. Camel's Conclusion

This research, like a detailed roadmap through the complexities of HIV prevention, provides valuable insights into the experiences of men who have sex with men using PrEP. Understanding the factors that influence adherence, both positive and negative, is essential for optimizing the effectiveness of PrEP and improving the health outcomes of this population. As a wise camel, I've always known that even the most well-traveled route can be met with unexpected challenges, and this study reminds us that continuous adaptation and support are essential for overcoming these obstacles.

Date :
  1. Date Completed 2013-12-16
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24093809

DOI: Digital Object Identifier

PMC3791030

Related Literature

Article Analysis
・Side Effects of emtricitabine and tenofovir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.